Neurotrope to Present at the Ladenburg Thalmann 2018 Healthcare Conference
NEW YORK, Sept. 27, 2018 /PRNewswire/ — Neurotrope, Inc. (NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease, today announced that Dr. Charles Ryan, Neurotrope’s Chief Executive Officer, will present a company overview at the Ladenburg Thalmann 2018 Healthcare Conference in New York on Tuesday, October 2nd, 2018 at 9:30 a.m. Eastern Time.
A live webcast of the presentation will be available on the “Events and Presentations” page in the “Investors and Media” section of the Company’s website at https://www.synaptogen.com/. The presentation will be archived on the Company’s website and be available for replay for 90 days.
Below is a direct link to the live webcast:
Neurotrope is at the forefront of developing a new approach to combating AD and other neurodegenerative diseases. The Company’s world-class science offers the potential to realize a paradigm shift to overcome one of today’s most challenging clinical problems — finding a way to slow or even prevent the progression of AD.
In addition to the Company’s Phase 2 trial of Bryostatin-1 in advanced AD, Neurotrope has also conducted preclinical studies of Bryostatin-1 as a potential treatment for Stroke, Traumatic Brain Injury, and Fragile X Syndrome, and Niemann-Pick Type C disease — rare genetic diseases for which only symptomatic treatments are currently available. The FDA has granted Orphan Drug Designation to Neurotrope for Bryostatin-1 as a treatment for Fragile X. Bryostatin-1 has already undergone testing in more than 1,500 people in cancer studies, thus creating a large safety data base that will further inform clinical trial designs.
Please visit www.neurotrope.com for further information.
Sam Martin / Ryan Baker